AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00856323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM
Description: Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
Study NCT02981056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Johnson's Baby Top-To-Toe Wash
Description: During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
Study NCT02981056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Johnson's Baby Lotion
Description: During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
Study NCT03533127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab + Carboplatin/Paclitaxel
Study NCT02981056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water (in lieu of bathing products)
Description: During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
Study NCT02850497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optical coherence tomography at 6 months
Description: 6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
Study NCT04143230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening for PC by means of two different screening tools
Description: Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
Study NCT04143230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for PC by means of two different screening tools
Description: Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
Study NCT03982238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Continuous subcutaneous insulin infusion therapy for 1 month
Study NCT03982238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
Study NCT03982238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
Study NCT01784588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solyx Single Incision Sling System
Description: Solyx Single Incision Sling System
Study NCT01784588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obtryx II Sling System
Description: Standard outside-in transobturator sling
Study NCT01734707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Allicor
Study NCT01734707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Allicor 150 mg tablet
Study NCT03619993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-body injector
Description: Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
Study NCT00696579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: 6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
Study NCT00696579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
Study NCT02264288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 x 10^6 cells
Description: 3 x 10\^6 cells administered on Study Days 1 and 8
Study NCT02264288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 x 10^6 cells
Description: 10 x 10\^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
Study NCT03619993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe
Description: For subcutaneous injection of a supportive medicine (Pegfilgrastim).
Study NCT01908140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide / Formoterol Fumarate
Study NCT01908140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol / Fluticasone
Study NCT03886441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone propionate
Description: Beclomethasone propionate inhaled twice daily during radiotherapy
Study NCT01230320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Denture fabrication technique
Description: Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases.
Study NCT01230320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Denture fabrication technique
Description: Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases.
Study NCT03417466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enlite 1 connected to iPro2 recorder
Description: Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
Study NCT00959426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
Study NCT00959426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
Study NCT01809886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
Study NCT01809886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
Study NCT02945124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: K tape
Description: Applying K tape to children to the lower limb muscles during motor activities.
Study NCT02818140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine TQL block
Description: Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
Study NCT02818140 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline TQL block
Description: Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
Study NCT02818140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02818140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02818140 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound
Study NCT02818140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT00005812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT02084069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT00340834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Description: Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Study NCT00340834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Study NCT00340834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon β-1a 30 µg
Description: Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Study NCT04562545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Twin Block
Description: a modified twin block design including jack screws to facilitate incemental advancement
Study NCT04562545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block Appliance set to maximum bite
Description: a traditional twin block set to maximum bite advancement at start of treatment
Study NCT03024424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early disclosure
Study NCT03024424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late disclosure
Study NCT02825147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Study NCT02825147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT02825147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02825147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02825147 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study NCT03073408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Closed loop control for propofol administration guided by the BIS.
Study NCT03073408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Manual control group: Propofol administration adjusted manually.
Study NCT01815580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atripla or Stribild
Description: Antiretroviral therapy
Study NCT02329743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: topical therapy
Study NCT02329743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RX-10045
Description: topical therapy
Study NCT01147393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-epratuzumab tetraxetan
Description: The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over \~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
Study NCT01815580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla or Stribild
Description: Antiretroviral therapy
Study NCT02305875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCN scoring
Description: Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
Study NCT02375269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC with a tourniquet
Study NCT02680587 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT (1-5 fractions) will be administered.
Study NCT00467714 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: rhinoplasty
Description: COLUMELLA STRUT PLACEMENT
Study NCT01147393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: veltuzumab
Description: Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
Study NCT02264288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 x 10^6 cells
Description: 30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
Study NCT02264288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical matching placebo administered IM on Study Days 1 and 8
Study NCT04001101 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RT and Anti-PD-1
Description: limited metastatic site radiation
Study NCT04001101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-PD-1
Description: anti-PD-1 therapy alone
Study NCT01481168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation (Medtronic)
Description: DDD+/-R pacing
Study NCT01787539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative Chemotherapy
Description: Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery.
Study NCT01481168 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pacemaker implantation (Medtronic)
Description: ODO pacing
Study NCT01935544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Study NCT01481168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (Medtronic)
Description: Loop recorder implantation
Study NCT01110772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate [InteguSEAL®]
Description: At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
Study NCT01110772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]
Description: At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
Study NCT04523584 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will undergo MR imaging of the liver. Liver PDFF will be measured.
Study NCT04523584 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.
Study NCT00212121 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: high dose boost
Description: high dose boost
Study NCT00212121 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose boost
Description: high dose boost
Study NCT00212121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: boost
Description: low dose versus high dose
Study NCT00212121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: boost
Description: low dose versus high dose
Study NCT01918540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hollow Centralizer
Description: The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
Study NCT01918540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Solid Centralizer
Description: The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
Study NCT01918540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MS-30 femoral stem
Description: This is the stem used in the study.
Study NCT04785859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BPD prediction
Description: The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time.
Study NCT00062010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interferon alpha
Description: Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
Study NCT00062010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid
Description: 13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
Study NCT00062010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
Study NCT04580121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7283420
Description: RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
Study NCT01882335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support for exclusive breastfeeding
Description: Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
Study NCT00901225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus Plerixafor
Description: On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected.